Cell-based vaccination against melanoma – background, preliminary results, and perspective

Dendritic cells and the control of immunity

1998 • 14,345 citations

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

1994 • 5,204 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

1998 • 2,615 citations

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

1988 • 2,196 citations

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

1998 • 2,106 citations

The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

1969 • 2,098 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Proliferating dendritic cell progenitors in human blood.

1994 • 1,922 citations

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

1996 • 1,854 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

1992 • 1,608 citations

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

1996 • 1,281 citations

Model Predicting Survival in Stage I Melanoma Based on Tumor Progression

1989 • 1,235 citations

Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions

1997 • 1,179 citations

Tumor Rejection After Direct Costimulation of CD8 ⁺ T Cells by B7-Transfected Melanoma Cells

1993 • 1,154 citations

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

1996 • 1,110 citations

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1995 • 1,097 citations

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1992 • 1,076 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2

1994 • 991 citations

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1990 • 926 citations

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

1996 • 922 citations

Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

1996 • 917 citations

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

1996 • 894 citations

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

1996 • 849 citations

Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice

1992 • 650 citations

Gene Therapy for Cancer: What Have We Done and Where Are We Going?

1997 • 635 citations

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

1990 • 628 citations

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1998 • 586 citations

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

1996 • 561 citations

Helper activity is required for the in vivo generation of cytotoxic T lymphocytes

1982 • 511 citations

Interleukin-10–Treated Human Dendritic Cells Induce a Melanoma-Antigen–Specific Anergy in CD8+ T Cells Resulting in a Failure to Lyse Tumor Cells

1999 • 499 citations

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1999 • 495 citations

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

1990 • 414 citations

Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection

1985 • 410 citations

Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

1992 • 410 citations

Cancer vaccines based on the identification of genes encoding cancer regression antigens

1997 • 395 citations

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma

1997 • 384 citations

Paracrine Cytokine Adjuvants in Cancer Immunotherapy

1995 • 373 citations

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1999 • 366 citations

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

1984 • 359 citations

Dendritic cells: from ontogenetic orphans to myelomonocytic descendants

1996 • 324 citations

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

1995 • 324 citations

Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.

1986 • 319 citations

Antitumor effect of locally produced CD95 ligand

1997 • 315 citations

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1990 • 300 citations

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.

1989 • 284 citations

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo

1996 • 274 citations

The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help.

1978 • 268 citations

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1995 • 264 citations

Cardiorespiratory effects of immunotherapy with interleukin-2.

1989 • 246 citations

Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

1994 • 245 citations

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

1988 • 239 citations

Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.

1992 • 232 citations

Alterations in the signal‐transducing molecules of T cells and nk cells in colorectal tumor‐infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease

1995 • 217 citations

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.

1993 • 210 citations

IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells.

1995 • 194 citations

Alterations in T cell receptor and signal transduction molecules in melanoma patients.

1995 • 192 citations

Active-specific immunotherapy for melanoma.

1990 • 186 citations

Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial

1998 • 183 citations

Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.

1994 • 181 citations

Direct evidence to support the immunosurveillance concept in a human regressive melanoma.

1994 • 171 citations

Tumour regression after intralesional injection of interleukin 2 (IL‐2) in bladder cancer. Preliminary report

1984 • 170 citations

Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.

1994 • 167 citations

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

1998 • 167 citations

Current therapy for cutaneous melanoma

1995 • 165 citations

Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma.

1998 • 147 citations

Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma

1998 • 138 citations

Vaccine therapy for malignant melanoma

1996 • 133 citations

Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression Antigens

1996 • 132 citations

Mechanisms Responsible for Signaling and Functional Defects

1998 • 132 citations

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

1997 • 128 citations

Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen.

1979 • 122 citations

B7-1 and interleukin 12 synergistically induce effective antitumor immunity.

1995 • 118 citations

From defined human tumor antigens to effective immunization?

1995 • 118 citations

High efficiency gene transfer into primary human tumor explants without cell selection.

1993 • 116 citations

The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor‐infiltrating lymphocytes

1994 • 115 citations

Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

1991 • 114 citations

Interleukin 10 production by human melanoma.

1996 • 113 citations

Perspective on allogeneic melanoma lysates in active specific immunotherapy.

1998 • 113 citations

Constitutive IL-10 Production Accounts for the High NK Sensitivity, Low MHC Class I Expression, and Poor Transporter Associated with Antigen Processing (TAP)-1/2 Function in the Prototype NK Target YAC-1

1998 • 113 citations

Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.

1996 • 111 citations

Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant.

1993 • 110 citations

A phase I clinical trial of immunotherapy with interferon-? gene-modified autologous melanoma cells

1997 • 108 citations

Multiple tumour-specific antigens expressed on a single tumour cell

1983 • 107 citations

Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation

1995 • 106 citations

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma

1989 • 105 citations

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines

1996 • 105 citations

Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells

1993 • 99 citations

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

1998 • 98 citations

Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Actiona

1993 • 97 citations

Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines.

1994 • 95 citations

Antigen‐presenting cells pulsed with unfractionated tumor‐derived peptides are potent tumor vaccines

1997 • 90 citations

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1992 • 89 citations

Active immunotherapy with allogeneic tumor cell vaccines: present status.

1998 • 89 citations

Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.

1995 • 88 citations

Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccines

1995 • 85 citations

Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells.

1992 • 83 citations

Human Melanoma-Reactive CD4+ and CD8+ CTL Clones Resist Fas Ligand-Induced Apoptosis and Use Fas/Fas Ligand-Independent Mechanisms for Tumor Killing

1998 • 83 citations

Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors.

1994 • 82 citations

Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells

1996 • 82 citations

Association of HLA phenotype with response to active specific immunotherapy of melanoma.

1992 • 81 citations

Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis.

1995 • 79 citations

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs

1994 • 78 citations

Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.

1998 • 77 citations

The Development of Gene Therapy for the Treatment of Cancer

1993 • 74 citations

Gene Therapy of Cancer: A Pilot Study of IL-4-Gene-Modified Fibroblasts Admixed with Autologous Tumor to Elicit an Immune Response. University of Pittsburgh

1994 • 74 citations

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

1997 • 69 citations

Studies of interferons in the therapy of melanoma.

1991 • 67 citations

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

1997 • 66 citations

A southeastern cancer study group phase I/II trial with vaccinia melanoma oncolysates

1986 • 65 citations

Induction of Antigen-Specific Tumor Immunity by Genetic and Cellular Vaccines against MAGE: Enhanced Tumor Protection by Coexpression of Granulocyte-Macrophage Colony-Stimulating Factor and B7-1

1996 • 64 citations

Interim Results of a Phase II Multicenter Clinical Trial Evaluating the Activity of a Therapeutic Allogeneic Melanoma Vaccine (Theraccine) in the Treatment of Disseminated Malignant Melanoma

1993 • 63 citations

Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine

1995 • 62 citations

Impaired Activation of NFκB in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, IκB

1998 • 59 citations

Immunotherapy of cancer with genetically modified tumor vaccines.

1996 • 59 citations

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

1997 • 57 citations

Autologous, hapten-modified vaccine as a treatment for human cancers.

1998 • 57 citations

In situ analysis of transforming growth factor-βs (TGF-β1, TGF-β2, TGF-β3and TGF-3 type II receptor expression in malignant melanoma

1995 • 55 citations

Role of Interferons in the Thearpy of Melanoma

1990 • 52 citations

Interferon‐activated tumor inhibition in vivo. Small amounts of interferon‐gamma inhibit tumor growth by eliciting host systemic immunoreactivity

1986 • 47 citations

Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine

1997 • 47 citations

Preparation and characterization of a polyvalent human melanoma antigen vaccine.

1986 • 47 citations

Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment

1995 • 46 citations

1975–1995 Revised anti-cancer serological response: Biological significance and clinical implications

1996 • 40 citations

Induction of Protective Anti-Tumor Immunity by Gene-Modified Dendritic Cells

1998 • 39 citations

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts

1997 • 39 citations

Immunotherapy of cancer using cytokine gene-modified tumor vaccines.

1994 • 38 citations

Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients

1998 • 38 citations

Coexpression of Interleukin-4 and B7.1 in Murine Tumor Cells Leads to Improved Tumor Rejection and Vaccine Effect Compared to Single Gene Transfectants and a Classical Adjuvant

1996 • 37 citations

Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors.

1993 • 32 citations

B7-1 Amplifies the Response to Interleukin-2-Secreting Tumor Vaccines In Vivo, but Fails to Induce a Response by Naive Cells In Vitro

1995 • 31 citations

Tumour inhibition by interleukin-2 at the tumour/host interface

1986 • 30 citations

Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10

1998 • 29 citations

Lymphokine-activated tumor inhibition in mice. Ability of a nonapeptide of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice.

1989 • 27 citations

Active specific immunization in the treatment of patients with melanoma.

1996 • 26 citations

Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma

1995 • 25 citations

Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors.

1996 • 24 citations

Active specific immunotherapy with vaccinia melanoma oncolysate.

1992 • 19 citations

Immunologic Host Defense in Melanoma: Delineation of Effector Mechanisms Involved and of Strategies for the Augmentation of Their Efficacy

1995 • 15 citations